Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM). Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Om Podcasten

Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COIVD outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.